ArticlePloS one2017
Metabolomics based predictive biomarker model of ARDS: A systemic measure of clinical hypoxemia.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Metabolomic signatures of early pathway disruptions and clinical outcomes in community-acquired pneumonia: a prospective case-control study.BMC pulmonary medicine · 2026Article
- Article
- The Role of the Respiratory Microbiome in Pneumonia.Clinics in chest medicine · 2026Review
- A human airway-on-a-chip microphysiological system for modeling chlorine gas toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS.BMJ open respiratory research · 2026Article
- Advancing omics technologies in acute respiratory distress syndrome: paving the way for personalized medicine.Intensive care medicine experimental · 2025Review
- Metabolic dysregulation in amyotrophic lateral sclerosis: insights fromMetabolic brain disease · 2025Article
- Review
- Metabolic signatures of acute respiratory distress syndrome: COVID versus non-COVID.American journal of physiology. Lung cellular and molecular physiology · 2024Review
- The Oxygen Cascade from Atmosphere to Mitochondria as a Tool to Understand the (Mal)adaptation to Hypoxia.International journal of molecular sciences · 2023Review
- Review
- The Role of Macrophages and Alveolar Epithelial Cells in the Development of ARDS.Inflammation · 2023Review
- Metabolomic characterization benefits the identification of acute lung injury in patients with type A acute aortic dissection.Frontiers in molecular biosciences · 2023Article
- CircRNAs in BALF exosomes and plasma as diagnostic biomarkers in patients with acute respiratory distress syndrome caused by severe pneumonia.Frontiers in cellular and infection microbiology · 2023Article
- Personalized medicine using omics approaches in acute respiratory distress syndrome to identify biological phenotypes.Respiratory research · 2022Review
- Plasma microRNA and metabolic changes associated with pediatric acute respiratory distress syndrome: a prospective cohort study.Scientific reports · 2022Article
- Inside the Alterations of Circulating Metabolome in Antarctica: The Adaptation to Chronic Hypoxia.Frontiers in physiology · 2022Article
- Experimental Technologies in the Diagnosis and Treatment of COVID-19 in Patients with Comorbidities.Journal of healthcare informatics research · 2022Review
- Metabolic signatures of ARDS and ARDS heterogeneity.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Association of Serum Mannose With Acute Respiratory Distress Syndrome Risk and Survival.JAMA network open · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advancements in ventilator technologies, lung supportive and rescue therapies, the outcome and prognostication in acute respiratory distress syndrome (ARDS) remains incremental and ambiguous. Metabolomics is a potential insightful measure to the diagnostic approaches practiced in critical disease settings. In our study patients diagnosed with mild and moderate/severe ARDS clinically governed by hypoxemic P/F ratio between 100-300 but with indistinct molecular phenotype were discriminated employing nuclear magnetic resonance (NMR) based metabolomics of mini bronchoalveolar lavage fluid (mBALF). Resulting biomarker prototype comprising six metabolites was substantiated highlighting ARDS susceptibility/recovery. Both the groups (mild and moderate/severe ARDS) showed distinct biochemical profile based on 83.3% classification by discriminant function analysis and cross validated accuracy of 91% using partial least squares discriminant analysis as major classifier. The predictive performance of narrowed down six metabolites were found analogous with chemometrics. The proposed biomarker model consisting of six metabolites proline, lysine/arginine, taurine, threonine and glutamate were found characteristic of ARDS sub-stages with aberrant metabolism observed mainly in arginine, proline metabolism, lysine synthesis and so forth correlating to diseased metabotype. Thus NMR based metabolomics has provided new insight into ARDS sub-stages and conclusively a precise biomarker model proposed, reflecting underlying metabolic dysfunction aiding prior clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.